 |
In this issue of Biopharm international -
best practices from Vironova biosafety |
|
 |
| |
Expert panel discussion:
Putting Viral Clearance Capabilities to the Test. |
"The key elements of a viral clearance validation are choice of process steps, viruses, points of sample withdrawal, and the correctness of scaling", says Gustav Gilljam, client project manager, Vironova Biosafety. “The process steps chosen must represent different mechanisms in virus inactivation/removal to be included. The viruses tested should include both enveloped and non-enveloped viruses, and both RNA and DNA viruses with different physical and chemical properties.”
continue to read the full article |
|
|
| |
Vironova Biosafety is part of the Vironova group of companies
Vironova Biosafety is a contract research organization (CRO) specialized in viral clearance studies for biological drugs.
Our office and laboratories are co-located with our mother company Vironova - a Swedish biotechnology company providing comprehensive hardware, software, and services for the analysis of nanoparticles.
Learn more about Vironova Biosafety |
|
| |
|
Copyright © 2018 *|LIST:COMPANY|*, All rights reserved.
|
